CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 93 filers reported holding CARDIFF ONCOLOGY INC in Q1 2022. The put-call ratio across all filers is 1.69 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,205 | -5.4% | 49,788 | 0.0% | 0.00% | – |
| Q2 2023 | $73,188 | -44.5% | 49,788 | -37.7% | 0.00% | – |
| Q1 2023 | $131,864 | +188.7% | 79,918 | +145.0% | 0.00% | – |
| Q4 2022 | $45,669 | -60.3% | 32,621 | -56.4% | 0.00% | – |
| Q3 2022 | $115,000 | -47.7% | 74,869 | -25.0% | 0.00% | – |
| Q2 2022 | $220,000 | +436.6% | 99,835 | +506.3% | 0.00% | – |
| Q1 2022 | $41,000 | -84.5% | 16,465 | -62.6% | 0.00% | – |
| Q4 2021 | $264,000 | -12.3% | 43,969 | -2.9% | 0.00% | – |
| Q3 2021 | $301,000 | +50.5% | 45,273 | +50.0% | 0.00% | – |
| Q2 2021 | $200,000 | -96.4% | 30,191 | -95.0% | 0.00% | -100.0% |
| Q1 2021 | $5,558,000 | +24065.2% | 600,208 | +46572.5% | 0.00% | – |
| Q4 2020 | $23,000 | -96.8% | 1,286 | -97.4% | 0.00% | – |
| Q3 2020 | $714,000 | – | 50,349 | +71827.1% | 0.00% | – |
| Q2 2020 | $0 | – | 70 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |